Effects of Bifidobacterium longum BB536 and Bifidobacterium breve MCC1274 on Body Composition in Normal and Overweight Adults in Randomized Placebo-Controlled Study

Abstract

Visceral fat accumulation is considered to be associated with a higher risk of chronic diseases. We investigated the effects of <i>Bifidobacterium longum</i> subsp. <i>longum</i> (<i>B. longum</i>) BB536 and <i>Bifidobacterium breve</i> (<i>B. breve</i>) MCC1274 on body composition, including visceral fat, in a randomized, parallel-group, placebo-controlled study. Participants were between 29 and 64 years of age and had a body mass index (BMI) of greater than 23 and less than 30. One hundred participants were randomly assigned to the probiotics group or placebo group. Participants were administered probiotic capsules containing 1 × 10¹⁰ colony-forming units (CFUs) of <i>B. longum</i> BB536 and 5 × 10⁹ CFU of <i>B. breve</i> MCC1274 or placebo capsules without bifidobacteria for 16 weeks. In the probiotics group, abdominal visceral fat area, total abdominal fat area, and serum triglyceride levels were significantly decreased compared to those in the placebo group. Additionally, the increase in BMI observed in the placebo group was significantly suppressed in the probiotics group. This study showed that <i>B. longum</i> BB536 and <i>B. breve</i> MCC1274 reduced abdominal visceral fat and total fat levels in healthy normal and overweight adults, suggesting their beneficial effects on body composition.